Search
AACR24: EpicentRx’s phase 2a using TGF-β trap to overcome checkpoint resistance
EpicentRx CEO Tony Reid and MD Andersen investigator Anthony Conley describe TGF-β data presented at AACR.
Apr 9, 2024
top of page
Search
Follow BiotechTV
Also look for unique social pages for BiotechTV U.
.png){kind=logo}
Sponsor Spotlight
Genezen is a contract development and manufacturing organization (CDMO) with unique technical expertise in lentiviral, retroviral, and adeno-associated viral vectors. Offering process development, GMP viral vector manufacturing, and analytics, we are dedicated to helping you deliver safe, pure, and potent advanced therapies to the patients who need them.
bottom of page